^
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: A1 - Approval
Eur J Cancer - 1 week
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: A1 - Approval
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Medullary Carcinoma
dacarbazine
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Medullary Carcinoma
denosumab
Sensitive: A2 - Guideline
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib tablet
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Medullary Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
RET M918T
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
KRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
NRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
HRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
RET mutation
Thyroid Gland Medullary Carcinoma
TPX 0046
Sensitive: C2 – Inclusion Criteria
RET mutation
Thyroid Gland Medullary Carcinoma
BOS-172738
Sensitive: C2 – Inclusion Criteria
RET V804*
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: C3 – Early Trials
RET C634*
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: C3 – Early Trials
RET M918T
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: C3 – Early Trials
RET C634R
Thyroid Gland Medullary Carcinoma
sorafenib
Sensitive: C3 – Early Trials
RET M918T
Thyroid Gland Medullary Carcinoma
sorafenib
Sensitive: C3 – Early Trials
RET V804M
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: C3 – Early Trials
RET M918T
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: C3 – Early Trials
RET V804L
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: C3 – Early Trials
RET mutation
Thyroid Gland Medullary Carcinoma
RET inhibitor
Sensitive: C3 – Early Trials
RET V804M + RET M918T + RET G810 + RET Y806
Thyroid Gland Medullary Carcinoma
selpercatinib
Resistant: C4 – Case Studies
NF1 mutation
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: C4 – Case Studies
RET M918T
Thyroid Gland Medullary Carcinoma
everolimus + vandetanib
Sensitive: C4 – Case Studies
ATM S978fs*12
Thyroid Gland Medullary Carcinoma
everolimus + vandetanib
Sensitive: C4 – Case Studies
ATM L804fs*4
Thyroid Gland Medullary Carcinoma
everolimus + vandetanib
Sensitive: C4 – Case Studies
RET C620R
Thyroid Gland Medullary Carcinoma
everolimus
Sensitive: C4 – Case Studies
RET M918T
Thyroid Gland Medullary Carcinoma
everolimus
Sensitive: C4 – Case Studies
RET C618R
Thyroid Gland Medullary Carcinoma
sorafenib
Sensitive: C4 – Case Studies
RET C634F
Thyroid Gland Medullary Carcinoma
sorafenib
Sensitive: C4 – Case Studies
RET M918T
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: C4 – Case Studies
ATM S978fs*12
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: C4 – Case Studies
ATM L804fs*4
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: C4 – Case Studies
RET L629P
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: C4 – Case Studies
RET D631_R635delinsG
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: C4 – Case Studies
RET V637R
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: C4 – Case Studies
RET exon 11 deletion
Thyroid Gland Medullary Carcinoma
sorafenib + tipifarnib
Sensitive: C4 – Case Studies
RET V804M + M918T
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: C4 – Case Studies
RET M918T
Thyroid Gland Medullary Carcinoma
sunitinib
Sensitive: C4 – Case Studies
RET Y900_S904delinsP
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: C4 – Case Studies
CCDC6-ALK fusion
Thyroid Gland Medullary Carcinoma
alectinib
Sensitive: C4 – Case Studies
RET C634W
Thyroid Gland Medullary Carcinoma
RAF265
Sensitive: D – Preclinical
RET M918T
Thyroid Gland Medullary Carcinoma
AMG 706
Resistant: D – Preclinical
RET C634W
Thyroid Gland Medullary Carcinoma
AMG 706
Resistant: D – Preclinical
RET C634W
Thyroid Gland Medullary Carcinoma
lenvatinib
Sensitive: D – Preclinical
KRAS G12R
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
BRAF mutation
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
PTEN mutation
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
RET mutation
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
NRAS mutation
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
KRAS mutation
Thyroid Gland Medullary Carcinoma
RTB101 + RAF265
Sensitive: D – Preclinical
RET C634W
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: D – Preclinical
BRAF V600E
Thyroid Gland Medullary Carcinoma
CI-1040
Sensitive: D – Preclinical
RET C634Y
Thyroid Gland Medullary Carcinoma
sorafenib
Sensitive: D – Preclinical